|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Veliparib>> Market Analysis Reports |
Market Analysis Reports of Veliparib |
|
CAS 912444-00-9 Veliparib Chemical Report & Database ... Consumption Report & Database definitions: Name: Veliparib: Veliparib; 2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide Synonyms ... -00-9 APPLICATIONS: Chemical or Reaction Intermediate The Veliparib Report & Database gives Market Consumption ... PARP Inhibitors Market Size, Trends, Analysis, and Outlook By Drug (Talazoparib, Veliparib, Olaparib, Others), By Indication (Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Others), By End-User (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), by Region, Country, Segment, and Companies, 2024-2030 ... PARP Inhibitors market By Drug (Talazoparib, Veliparib, Olaparib, Others), By Indication (Ovarian Cancer ... Global Market Report of ABT888 (CAS 912444-00-9) December 2024 Global PARP Inhibitor Industry Research Report, Competitive Landscape, Market Size, Regional Status and Prospect ... into: Lynparza Niraparib Rucaparib Talazoparib Veliparib Others In Chapter 6 and Chapter 7.4, based ... Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. “Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023” report highlights: Current Market Trends & ... PARP INHIBITORS - COMPETITIVE LANDSCAPE, PIPELINE AND MARKET ANALYSIS, 2018 This report can be delivered to the clients within 48 hours 'PARP Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report ... CAS 912445-05-7 ABT-888 Chemical Report & Database ... -2-pyrrolidinyl]-1H-benzimidazole-4-carboxamide dihydrochloride; Veliparib dihydrochloride Synonyms: 2-[(2R)-2-Methyl-2-pyrrolidinyl]-1H- ... benzimidazole-4-carboxamide dihydrochloride; Veliparib dihydrochloride Chemical Registry number: ... Global RNA Polymerase Inhibitor Market Growth 2023-2029 ... countries. Market Segmentation: Segmentation by type Veliparib Rucaparib Talazoparib Niraparib Others Segmentation ... Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Growth 2024-2030 ... and countries. Segmentation by Type: Talazoparib Veliparib Olaparib Other Segmentation by Application: Ovarian ... Glioblastoma: KOL Insight ... in GBM? What do KOLs think of AbbVie’s veliparib, AstraZeneca’s olaparib and BeiGene’s BGB ... ; AbbVie) dianhydrogalactitol (VAL-083; DelMar) veliparib (AbbVie) flucytosine (Toca FC; Tocagen) Imfinzi ... Global RNA Polymerase Inhibitor Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 ... markets. Market segment by Type, covers Veliparib Rucaparib Talazoparib Niraparib Others Market ... 2025-2030 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Outlook Market Size, Share & Trends Analysis Report By Player, Type, Application and Region ... Teva Pharmaceutical Industries By Type Talazoparib Veliparib Olaparib Other By Application Ovarian Cancer ... Non-Small Cell Lung Cancer: KOL Insight ... , Array’s/AstraZeneca’s selumetinib and AbbVie’s veliparib). How the treatment landscape for ... Ovarian Cancer [2017] ... full list now > Phase III Veliparib (ABT-888; AbbVie) Atezolizumab (Tecentriq ... Colorectal Cancer [2017] ... ) OncoVAX (Vaccinogen) Early Stage MOAs (P1/P2) Veliparib (ABT-888; AbbVie) Entinostat (Syndax ... Ovarian Cancer: KOL Insight ... (bevacizumab; Roche) Phase III Therapies Veliparib (ABT-888; AbbVie Atezolizumab (Tecentriq ... Anaplastic Astrocytoma - Pipeline Review, 2019 ... carmustine Carboplatin Vinchristine sulfate Leflunomide Veliparib Dabrafenib TAS-120 CB-839 Selumetinib ... Epigenetic Therapeutics: Global Markets Report Scope: This report is a comprehensive study of the global market for epigenetic therapeutics. It describes the epigenetic therapeutics market, which is segmented by product type and region. Based on product type, the market is segmented into PRAP ... Global DNA Damage Response Drugs Market: Focus on Commercialized Drugs, Potential Pipeline Drugs, Application, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030 Hard copy option is available on any of the options above at an additional charge of $500. Please email us at Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review ... |